Amer Zureikat is an Oncology physician affiliated with UPMC Hillman Cancer Center. OpenAlex indexes 620 publications with 15,182 citations (h-index 59); ClinicalTrials.gov lists 1 registered study matched to this name. By OpenAlex citation count, this profile ranks in the top 10% of Surgical Oncology profiles in the findmyKOL directory.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
5150 Centre Ave
Suite 413
Pittsburgh, PA 152321309
Telephone
412-623-4861Registry record last updated 29 Nov 2011.
Clinical trials
- Chemokine-Modulatory Regimen for Recurrent Resectable Colorectal Cancer
Sponsor: Roswell Park Cancer Institute
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
5 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Medtronic, Inc.Program year20254 payments
- INTUITIVE SURGICAL, INC.Program year20251 payment
- DISTALMOTION USProgram year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
100%Antidiarrheal microorganisms53%Creon86%Zenpep14%Part D<11 patientsProton pump inhibitor47%Pantoprazole Sodium100%Part D≥37 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Long‐term oncologic outcomes of robotic and open pancreatectomy in a national cohort of pancreatic adenocarcinoma
Journal of Surgical Oncology
2020 - Serum CA19-9 Response to Neoadjuvant Therapy Predicts Tumor Size Reduction and Survival in Pancreatic Adenocarcinoma
Annals of Surgical Oncology
2020
Similar KOLs
Other experts from the same institution or the same specialty.
Udai Kammula, MD
UPMC Hillman Cancer Center
Antoinette Wozniak, MD
UPMC Hillman Cancer Center
Mounzer Agha, MD
UPMC Hillman Cancer Center
Diwakar Davar, MBBS, MSc
UPMC Hillman Cancer Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”